ABBV vs MRK
By Alex · Tickerpine
AbbVie Inc. vs Merck & Company, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | MRK |
|---|---|---|
| Price | $248.76 | $132.92 |
| Market cap | $439.59B | $327.94B |
| P/E ratio | 70.5 | 106.3 |
| ROE | — | 6.96% |
| Profit margin | 9.80% | 4.77% |
| Revenue growth | 10.20% | 5.10% |
| Dividend yield | 2.77% | 2.56% |
| Beta | 0.28 | 0.21 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs MRK in plain English
- ABBV is the bigger company — about 1.3× the market cap of MRK.
- ABBV is cheaper on earnings (P/E 70.5 vs 106.3).
- ABBV is growing revenue faster (10% vs 5%).
- ABBV has the higher dividend yield (2.77% vs 2.56%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.